Study wrapper · #712
Reduced Circulating MOTS-c Levels in Hashimoto's Thyroiditis Reflect Integrated Autoimmune and Metabolic Dysregulation: A Cross-Sectional Study.
Editor's note
This cross-sectional human study measured circulating MOTS-c in 90 patients with Hashimoto's thyroiditis versus 90 matched controls, finding significantly lower MOTS-c in patients and inverse correlations with BMI, fasting glucose, HbA1c, HOMA-IR, TSH, CRP and thyroid autoantibodies; regression flagged Hashimoto's and insulin resistance as independent predictors of lower MOTS-c. Importantly, this examines endogenous MOTS-c as a biomarker, not MOTS-c supplementation, so it speaks to associations rather than to peptide administration. A cross-sectional design cannot establish direction or causation (low MOTS-c could be consequence, not cause). It is genuine human data relevant to MOTS-c biology, but should not be read as evidence that taking MOTS-c does anything. Associational human evidence only.
Plain-language abstract
MOTS-c is a peptide the body makes that is tied to metabolism and inflammation. This study measured natural MOTS-c levels in the blood of 180 people: 90 with Hashimoto's thyroiditis (an autoimmune thyroid condition) and 90 healthy, age- and sex-matched comparisons. People with Hashimoto's had significantly lower MOTS-c. Lower MOTS-c also went hand in hand with higher body-mass index, blood sugar, long-term sugar marker (HbA1c), insulin resistance, thyroid-stimulating hormone, an inflammation marker, and thyroid antibodies. Statistical analysis pointed to Hashimoto's and insulin resistance as the strongest links to low MOTS-c. Because this is a one-time snapshot, it cannot tell whether low MOTS-c contributes to the disease or simply reflects it. Importantly, it measured the body's own MOTS-c, not the effect of taking MOTS-c as a supplement, so it shows an association, not a treatment effect.